| |
Deliver high performance and continuity for your next obesity trial. IQVIA’s digital ecosystem drives data accuracy, deeper insights and more proactive decision-making. Accelerate your obesity clinical research success — download the case study! 
|
|
|
Wednesday, June 18, 2025 | 2pm ET / 11am PT Real-world data is a powerful asset for enhancing oncology trial design, supporting regulatory submissions, and demonstrating real-world value. But as the stakes grow, so does the ethical responsibility to use RWD with transparency, fairness, and patient-centered rigor. This webinar will explore how to ethically and effectively incorporate RWD into oncology clinical research. Sign up now to join us! 
|
|
| By Kevin Dunleavy Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical companies from advertising directly to consumers. The End Prescription Drug Ads Now Act would prohibit drugmakers from promoting prescription drugs through television, radio, print, digital platforms and social media. |
|
|
|
By Gabrielle Masson The FDA is introducing a new priority voucher program designed to shorten the drug review process time from 10 to 12 months down to one or two months, according to the agency. |
By Fraiser Kansteiner,Zoey Becker,Eric Sagonowsky,Angus Liu,Kevin Dunleavy The pay packages handed out for last year’s work seem to further cement a new status quo in the realm of CEO compensation, as several recently appointed pharma leaders settle into their roles and companies establish their market positions heading into the second half of the decade. |
By Angus Liu A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy gene therapy’s safety profile. |
|
Tuesday, June 24, 2025 | 10am ET / 7am PT Learn how digital adoption platforms (DAPs) can help drug developers speed time to market by improving efficiency, reducing errors, and streamlining collaboration, regulatory submissions, and clinical milestones—without compromising quality or compliance. Register now. 
|
|
By Nick Paul Taylor Biogen has emerged as a front-runner at the Cannes Lions International Festival of Creativity, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia. But the biotech was absent from the Health & Wellness category, where Bristol Myers Squibb and Novartis led pharma representation. |
By Conor Hale Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million last month and planned to incorporate the DNA company’s assets in its R&D. |
By Nick Paul Taylor Gilead is laying off 36 people as part of the rethink that saw it scrap plans to expand a biologics facility in California. |
By Angus Liu Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease. |
By Darren Incorvaia Johnson and Johnson is providing a first look at clinical data for its dual-targeting blood cancer CAR-T program. |
By Fraiser Kansteiner With the industry in a holding pattern, President Donald Trump is again beating the drum for pharmaceutical import tariffs—though the exact nature and timing of their implementation remains unclear as ever. |
By Darren Incorvaia As Harvard University reels from extensive cuts to federal funding by the Trump Administration, one researcher there has secured his lab’s future by looking abroad. Gökhan Hotamışlıgil, M.D., Ph.D., has secured about $39 million from a Turkish investment group to support the next 10 years of his group’s research on new antibodies for obesity and other metabolic diseases. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
Executive Summary Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
